title: Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.
abstract: OBJECTIVE
  In recent years, there has been a growing interest in developing adequate treatments for patients with a diagnosis of schizophrenia and a comorbid substance use disorder (SUD). In the present paper we aim to critically review published reports on the use of conventional and second-generation antipsychotics in the treatment of patients with schizophrenia and comorbid SUD, to provide clinicians with a clearer view of the pharmacological treatment of this highly prevalent dual diagnosis based upon the evidence arising from the scientific literature.
  
  
  METHODS
  A search of the relevant literature from Medline, PsycLIT and EMBASE databases, included in the Science Citation Index, and available up to November 2006 was conducted using the terms: 'schizophrenia', 'substance use disorder' and 'antipsychotics'.
  
  
  RESULTS
  While research on the use of conventional antipsychotics has remained limited, the majority of studies suggest the effectiveness of second-generation antipsychotics, particularly clozapine, for patients with schizophrenia and a comorbid substance use disorder.
  
  
  CONCLUSIONS
  In the absence of randomized controlled trials that could provide more reliable information, clinical decisions may need to rely on indirect data provided by the increasing number of case reports, open trials and retrospective studies showing a decrease in cigarette smoking, alcohol, cocaine or cannabis use and an improvement of overall psychiatric symptoms.
authors.affiliation: Department of Psychiatry, Hospital San Rafael, Barcelona, Spain. 12636LSM@comb.es
authors.forename: Luis
authors.initials: L
authors.lastname: San
authors.forename: Belen
authors.initials: B
authors.lastname: Arranz
authors.forename: Jose
authors.initials: J
authors.lastname: Martinez-Raga
mesh_terms: D000437:Alcoholism / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D019970:Cocaine-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D003131:Combined Modality Therapy; D015897:Comorbidity; D003430:Cross-Sectional Studies; D017831:Diagnosis, Dual (Psychiatry); D006801:Humans; D002189:Marijuana Abuse / Q000175:diagnosis / Q000453:epidemiology / Q000534:rehabilitation; D012559:Schizophrenia / Q000175:diagnosis / Q000453:epidemiology / Q000534:rehabilitation*; D016540:Smoking Cessation / Q000706:statistics & numerical data; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000534:rehabilitation*
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine